Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34468363 | 1.00 | NR1H2 (0.51) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL4677686 | 1.00 | NR1H2 (0.51) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL5881516 | 1.00 | NR1H2 (0.51) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL29178586 | 0.86 | CHRM2 (0.47) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL4676909 | 0.86 | CHRM2 (0.47) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL4681123 | 0.86 | CHRM2 (0.47) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL4684359 | 0.84 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL29655394 | 0.84 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL1481922 | 0.84 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL3938157 | 0.84 | NR1H2 (0.49) | NR1H2CHRM2CHRM1CHRM3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | SPARK BIOPHARMA, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4365175-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | Spark Biopharma, Inc. (KR) | 2024-05-08 | — | — | EP | disclosed |
| CN-117897386-A | Benzopyran derivatives and uses thereof | 斯帕克生物制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| WO-2023220577-A1 | 6,6A,7,8,9,10-HEXAHYDRO-5H-PYRAZINO[1',2':4,5]PYRAZINO[2,3-C]PYRIDAZINE DERIVATIVES AS SMARCA4 PROTEIN DEGRADERS FOR THE TREATMENT OF CANCER | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-115362156-A | Muscarinic receptor 4 antagonists and methods of use | 纽罗克里生物科学有限公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042911-A1 | NOVEL BENZOPYRAN DERIVATIVE AND USE THEREOF | MYD88, MYADM, CD14 | NR1H2 2674/4885CHRM2 1212/4885CHRM1 2186/4885 |
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | NR1H2 1100/4885CHRM2 833/4885CHRM1 212/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | NR1H2 1100/4885CHRM2 833/4885CHRM1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.